DK4112069T3 - Komponenter i plasminogen-aktiveringsvejen til brug ved behandling af forhøjet blodtryk - Google Patents

Komponenter i plasminogen-aktiveringsvejen til brug ved behandling af forhøjet blodtryk

Info

Publication number
DK4112069T3
DK4112069T3 DK21760438.8T DK21760438T DK4112069T3 DK 4112069 T3 DK4112069 T3 DK 4112069T3 DK 21760438 T DK21760438 T DK 21760438T DK 4112069 T3 DK4112069 T3 DK 4112069T3
Authority
DK
Denmark
Prior art keywords
treatment
components
blood pressure
high blood
activation pathway
Prior art date
Application number
DK21760438.8T
Other languages
English (en)
Inventor
Jinan Li
Original Assignee
Talengen Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Int Ltd filed Critical Talengen Int Ltd
Application granted granted Critical
Publication of DK4112069T3 publication Critical patent/DK4112069T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK21760438.8T 2020-02-26 2021-02-26 Komponenter i plasminogen-aktiveringsvejen til brug ved behandling af forhøjet blodtryk DK4112069T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010119730 2020-02-26
PCT/CN2021/078200 WO2021170099A1 (zh) 2020-02-26 2021-02-26 一种预防和治疗血压异常病症的方法和药物

Publications (1)

Publication Number Publication Date
DK4112069T3 true DK4112069T3 (da) 2025-09-29

Family

ID=77490734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21760438.8T DK4112069T3 (da) 2020-02-26 2021-02-26 Komponenter i plasminogen-aktiveringsvejen til brug ved behandling af forhøjet blodtryk

Country Status (10)

Country Link
US (1) US20230139956A1 (da)
EP (1) EP4112069B1 (da)
JP (2) JP7616698B2 (da)
KR (1) KR20220143913A (da)
CN (1) CN115551534A (da)
CA (1) CA3169325A1 (da)
DK (1) DK4112069T3 (da)
ES (1) ES3048450T3 (da)
TW (1) TWI853151B (da)
WO (1) WO2021170099A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143906A1 (zh) * 2020-01-17 2021-07-22 泰伦基国际有限公司 一种治疗神经损伤及其相关病症的方法
EP4140498A4 (en) 2020-05-11 2023-11-01 Talengen International Limited Method and drug for treating spinal muscular atrophy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US20030125233A1 (en) * 2000-06-27 2003-07-03 Peter Carmeliet Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
US20120027558A1 (en) * 2010-07-28 2012-02-02 Weeden Todd M Tire storage system
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778307A (zh) * 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
US11338022B2 (en) * 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
CN105535950A (zh) * 2016-02-02 2016-05-04 武汉真福医药股份有限公司 制备纤溶酶组合物的方法及其应用
CN108210899A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗组织器官纤维化的药物及其用途
CN108210915A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 改善心脏病变的药物及其用途
CN108210893A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肾纤维化的药物及其用途
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
CN108210917A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CN108210909A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂质肾损伤的药物及其用途
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
US11938172B2 (en) * 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug

Also Published As

Publication number Publication date
EP4112069A4 (en) 2023-09-27
CN115551534A (zh) 2022-12-30
JP2025000825A (ja) 2025-01-07
EP4112069B1 (en) 2025-08-06
TW202140067A (zh) 2021-11-01
JP2023514819A (ja) 2023-04-11
EP4112069A1 (en) 2023-01-04
JP7616698B2 (ja) 2025-01-17
KR20220143913A (ko) 2022-10-25
TWI853151B (zh) 2024-08-21
WO2021170099A1 (zh) 2021-09-02
US20230139956A1 (en) 2023-05-04
ES3048450T3 (en) 2025-12-10
CA3169325A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
DK4084791T3 (da) Specifikke tryptaminer til brug i behandlingen af humørsvingninger
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
DK3324994T3 (da) Nx-1207 til brug i fremgangsmåder til mindskning af behovet for kirurgi hos patient, som lider af godartet prostatisk hyperplasi
MX378283B (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreina plasmatica.
DK4076461T3 (da) Lumateperon til brug ved behandling af skizofreni
EP3471717A4 (en) TREATMENT OF PLATE CELL CARCINOMAS WITH ERK INHIBITORS
EP4338793A4 (en) High-frequency treatment handpiece
DK3556383T5 (da) Plasminogen til anvendelse ved behandling af diabetes
HUE067617T2 (hu) Készítmények a magas vérnyomás kezelésére
DK3405159T3 (da) Behandling og forebyggelse af retinale vaskulære sygdomme ved fotokoagulation
PL3634415T3 (pl) Kompozycje okulistyczne zawierające brymonidynę i ketotifen do zastosowania w leczeniu alergii
DK3465214T3 (da) Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter
LT3972604T (lt) Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui
DK4340842T3 (da) Sotorasib til anvendelse ved behandling af kræft
IL289758A (en) Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
IL248468A0 (en) Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
DK4419526T3 (da) Heterocykliske forbindelser til anvendelse i behandlingen af cancer
CL2007002652A1 (es) Compuestos derivados de isoserina, inhibidores del factor de coagulacion de la sangre ixa; procedimiento de preparacion; y su uso para preparar un medicamento para tratar enfermedades acompanadas de trombosis, embolias, hipercoagulabilidad o cambios
IL312635A (en) Pharmaceutical combinations for treatment of hbv
DK3271392T3 (da) Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia
EP4317384A4 (en) Aqueous processing liquid
LT4188389T (lt) Dapagliflozinas, skirtas panaudoti taikant lėtinės inkstų ligos gydymo būdą
PL4161528T3 (pl) Kombinacja ruksolitynibu z incb057643 do stosowania w leczeniu nowotworów mieloproliferacyjnych